IL288655A - Preparations and methods for the treatment of central nervous system disorders - Google Patents

Preparations and methods for the treatment of central nervous system disorders

Info

Publication number
IL288655A
IL288655A IL288655A IL28865521A IL288655A IL 288655 A IL288655 A IL 288655A IL 288655 A IL288655 A IL 288655A IL 28865521 A IL28865521 A IL 28865521A IL 288655 A IL288655 A IL 288655A
Authority
IL
Israel
Prior art keywords
compositions
methods
nervous system
central nervous
system disorders
Prior art date
Application number
IL288655A
Other languages
English (en)
Hebrew (he)
Original Assignee
Paxmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paxmedica Inc filed Critical Paxmedica Inc
Publication of IL288655A publication Critical patent/IL288655A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL288655A 2019-06-07 2021-12-02 Preparations and methods for the treatment of central nervous system disorders IL288655A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858621P 2019-06-07 2019-06-07
PCT/US2020/031217 WO2020247127A1 (en) 2019-06-07 2020-05-02 Compositions and methods for treating central nervous system disorders

Publications (1)

Publication Number Publication Date
IL288655A true IL288655A (en) 2022-02-01

Family

ID=73652889

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288655A IL288655A (en) 2019-06-07 2021-12-02 Preparations and methods for the treatment of central nervous system disorders

Country Status (8)

Country Link
US (1) US20220226268A1 (cg-RX-API-DMAC7.html)
EP (1) EP3979985A4 (cg-RX-API-DMAC7.html)
JP (1) JP7749169B2 (cg-RX-API-DMAC7.html)
CN (1) CN114340597B (cg-RX-API-DMAC7.html)
AU (1) AU2020288999A1 (cg-RX-API-DMAC7.html)
CA (1) CA3142842A1 (cg-RX-API-DMAC7.html)
IL (1) IL288655A (cg-RX-API-DMAC7.html)
WO (1) WO2020247127A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021319064A1 (en) * 2020-07-29 2023-03-23 Perfect Daylight Limited Methods of manufacture of suramin
US20230390223A1 (en) * 2020-10-22 2023-12-07 Paxmedica, Inc. Administration of antipurinergic compositions for treating nervous system disorders
EP4229035A4 (en) * 2020-10-22 2024-07-31 Paxmedica, Inc. INTRANASALY ADMINISTRATION OF SURAMIN FOR THE TREATMENT OF NERVOUS SYSTEM DISEASES
JP2024532288A (ja) * 2021-08-23 2024-09-05 パックスメディカ, インコーポレイテッド 抗プリン作動薬を用いて神経系障害を処置するための方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5012285A (en) * 1984-10-12 1986-05-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
JP2003506458A (ja) * 1999-08-11 2003-02-18 ジョセフ ピサ, シクロデキストリン誘導体の包接複合体形成の増強
JP2005519075A (ja) * 2002-02-25 2005-06-30 リフジャスロウン エイチエフ 吸収促進剤
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
FR2912591B1 (fr) * 2007-02-12 2009-05-01 Oberthur Card Syst Sa Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile.
AR062239A1 (es) * 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
US20120070487A1 (en) * 2010-03-24 2012-03-22 Aegis Therapeutics Llc Alkylsaccharide compositions with nutraceuticals
GB201401904D0 (en) * 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
FR3025110B1 (fr) * 2014-09-02 2016-12-23 Univ Francois-Rabelais De Tours Dispositif de pulverisation nasale de produit fluide
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
HRP20250215T1 (hr) * 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
WO2018148262A1 (en) * 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
WO2018148580A1 (en) * 2017-02-09 2018-08-16 Perfect Daylight Limited Methods for autism spectrum disorder pharmacotherapy
US11110060B2 (en) * 2017-10-25 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Also Published As

Publication number Publication date
US20220226268A1 (en) 2022-07-21
EP3979985A4 (en) 2023-05-03
CA3142842A1 (en) 2020-12-10
JP2022535920A (ja) 2022-08-10
WO2020247127A1 (en) 2020-12-10
EP3979985A1 (en) 2022-04-13
AU2020288999A1 (en) 2022-02-03
CN114340597B (zh) 2025-01-28
CN114340597A (zh) 2022-04-12
JP7749169B2 (ja) 2025-10-06

Similar Documents

Publication Publication Date Title
IL285649A (en) Azepino-indoles and other heterocyclics for the treatment of brain disorders
IL290575A (en) Preparations and methods for the treatment of disorders related to repetitive DNA
IL289173A (en) Preparations and methods for the treatment of central nervous system disorders
IL275506A (en) Preparations and methods for the treatment of central nervous system disorders
IL275562A (en) Preparations and methods for the treatment of central nervous system disorders
EP4010072A4 (en) TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
EP3746135A4 (en) METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
IL286868A (en) Compounds and methods that monitor the expression of genes in the central nervous system
EP3917620A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS
EP3999110A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES
IL289172A (en) Preparations and methods for the treatment of central nervous system disorders
SG11202011151VA (en) Compositions and methods for reducing spliceopathy and treating rna dominance disorders
SG11202102349PA (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
IL275985A (en) Preparations and methods for the treatment of retinal disorders
IL270114B1 (en) Methods and compounds for the treatment of neurological diseases
IL279634A (en) Preparations and methods for the treatment and prevention of neurological disorders
EP3979985A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
EP3917622A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS RELATED TO ANXIETY
IL287831A (en) Oxymetazoline compounds and methods for treating eye diseases
IL274067A (en) Kinase inhibitors for the treatment of central and peripheral nervous system disorders
IL286571A (en) Compounds and methods for the treatment of neurodegenerative disorders
SG11202102982QA (en) Methods of treating myeloproliferative disorders
EP3256151A4 (en) Methods and compositions for treating muscle disease and disorders
IL310559A (en) Methods for treating disorders of the nervous system with antipurinergic substances
IL311852A (en) Preparations and methods for the treatment of neurological disorders